Skip to main content
Premium Trial:

Request an Annual Quote

Horizon Discovery Raises $9.9M in Series C Financing

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Horizon Discovery has closed a Series C round of financing, raising £6.25 million ($9.9 million).

The Cambridge, UK-based firm said the funds will be used to improve its core Genesis and X-Man technology platforms, address new markets, and begin targeting therapeutics outside of its initial focus on cancer. Its Genesis technology is a virally-mediated , gene-engineering technology, and its X-Man models are genetically-defined, patient-relevant human cells lines used for modeling disease-causing mutations in cancer patients.

The round was led by European venture capital firm DFL Esprit. Other investors included Roche Venture Fund, Jonathan Milner, and David Evans, who currently is chairman of Immunodiagnostics Systems.

As part of the financing, Horizon appointed DFJ Esprit Partner Nigel Pitchford to its board as investor director and Evans as non-executive director.

The Scan

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.

Researchers Reprogram Plant Roots With Synthetic Genetic Circuit Strategy

Root gene expression was altered with the help of genetic circuits built around a series of synthetic transcriptional regulators in the Nicotiana benthamiana plant in a Science paper.

Infectious Disease Tracking Study Compares Genome Sequencing Approaches

Researchers in BMC Genomics see advantages for capture-based Illumina sequencing and amplicon-based sequencing on the Nanopore instrument, depending on the situation or samples available.

LINE-1 Linked to Premature Aging Conditions

Researchers report in Science Translational Medicine that the accumulation of LINE-1 RNA contributes to premature aging conditions and that symptoms can be improved by targeting them.